FTRD® effective for duodenal neuroendocrine tumors

FTRD® for duodenal neuroendocrine tumors (dNETs) shows high technical success as well as R0 resection rates, and could become the treatment of choice

Key findings

• R0 resection rates were 71.9% (123/171)
• Technical success was 95.9% (164/171)
• Adverse events requiring surgery occurred in 1.2% of cases (2/171)

Study details

• 171 patients across 35 centers worldwide were included
• Median size of the lesions was 10mm
• 83.6% of lesions were in the duodenal bulb
• R0 resection rates were influenced by location of the lesion, i.e. 62% in the proximal third of the bulb and 83.9% in more distal location (p=0.002)

Wannhoff A, Nabi Z, Moons LMG, Haber G, Ge PS, Dertmann T, Deprez PH, Korcz W, Bouvette C, Mueller J, Tribonias G, Grande G, Kim JJ, Weich A, Heinrich H, Mollenkopf M, George J, Pioche M, Azzolini F, Kouladouros K, Boger P, Hayee B, Bilal M, Bastiaansen BAJ, Caca K. International, Multicenter Analysis of Endoscopic Full-Thickness Resection of Duodenal Neuroendocrine Tumors. Am J Gastroenterol. 2025. doi: 10.14309/ajg.0000000000003409